Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome
NCT03695822 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL
Last updated 2019-03-07
Summary
We will get the impact of mirabegron on psychological distress, urethra and bladder blood flow and c reactive protein.
Conditions
- Overactive Bladder Syndrome
Interventions
- DRUG
-
Mirabegron 25mg
The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
Sponsors & Collaborators
-
Far Eastern Memorial Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-12-24
- Primary Completion
- 2019-01-21
- Completion
- 2019-01-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome
NCT05040984 ·Status: UNKNOWN
-
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
NCT03572231 ·Status: COMPLETED
-
Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study
NCT05946902 ·Status: UNKNOWN ·Phase: PHASE4
-
Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women
NCT02981459 ·Status: WITHDRAWN ·Phase: PHASE4
-
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
NCT02540707 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial
NCT07114640 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder
NCT06479720 ·Status: RECRUITING ·Phase: PHASE4
-
Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial
NCT05188742 ·Status: UNKNOWN ·Phase: PHASE4
-
MIrabegron With oveRACtive bLadder Symptoms in mEn
NCT02361502 ·Status: UNKNOWN ·Phase: PHASE4
-
Predictors for Retreatement of OAB After DC Mirabegron
NCT04550702 ·Status: COMPLETED
-
Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder
NCT03558919 ·Status: COMPLETED ·Phase: PHASE4
-
Developing a Simple Test to Diagnose Overactive Bladder
NCT05572918 ·Status: UNKNOWN
-
Does Mirabegron Have a Positive Impact on Sexual Function in Females With Overactive Bladder
NCT04511273 ·Status: UNKNOWN
-
Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)
NCT02410135 ·Status: COMPLETED
-
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
NCT02386072 ·Status: COMPLETED
-
Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes
NCT07025642 ·Status: RECRUITING ·Phase: NA
-
Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy
NCT07337252 ·Status: COMPLETED
-
Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms
NCT04420533 ·Status: COMPLETED ·Phase: NA
-
Bladder Wall Blood Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarincs for Female Overactive Bladder Syndrome.
NCT01282840 ·Status: COMPLETED ·Phase: NA
-
Mirabegron and Urinary Urgency Incontinence
NCT02495389 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity
NCT06197295 ·Status: RECRUITING ·Phase: PHASE4
-
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
NCT04562090 ·Status: COMPLETED ·Phase: PHASE4
-
Study of ONO-8577 in Patients With Overactive Bladder
NCT03106623 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00688688 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
NCT03602508 ·Status: COMPLETED